By specifically targeting the BCR-ABL fusion protein in CML and the KIT receptor tyrosine kinase in GIST, imatinib effectively inhibits the aberrant kinase activity, leading to the inhibition of cell proliferation and induction of apoptosis [128]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.